中国平安(02318.HK)领投1,500万美元人工智能软件供应商Riverain
中国平安(02318.HK)公布,平安全球领航基金领投1,500万美元於领先的临床人工智能软件供应商Riverain Technologies。该公司的人工智能软件可有效地在最早期阶段筛检肺部疾病。
集团指,Riverain Technologies向全球领先医院推广先进人工智能成像软件。该软件显着提高了临床医生准确有效检测胸部电脑断层扫描和X射线图像中癌症和其他细胞异常的能力。Riverain Technologies的专利软件工具套件ClearRead由医疗成像市场最先进的人工智能和机器学习方法支持,并经美国食品药物管理局批准可於诊所或云平台上使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.